Cd19-specific antibody constructs and compositions thereof
OwnerJeremy KINDER, Neal VAN HOEVEN +3inventors
InventorsJeremy KINDER, Neal VAN HOEVEN, Hallee A. WRIGHT, Jesse GREEN, Adam J. JOHNSON
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD19. Also disclosed are chimeric antigen receptors and chimeric antigen receptor transgenes comprising an antigen binding domain that specifically binds human CD19. Also described herein are immune cells, viral vectors, and other compositions containing the antibodies, antibody binding fragments, chimeric antigen receptors, and/or chimeric antigen receptor transgenes.
Claims156
An isolated polypeptide comprising an amino acid sequence selected from SEQ ID NOs:
- 19-21.
An isolated polypeptide comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs:
- 19-21.
An isolated polypeptide comprising an amino acid sequence selected from SEQ ID NOs:
- 22-24.
An isolated polypeptide comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs:
- 22-24.
An isolated polypeptide comprising an amino acid sequence selected from:
- a) SEQ ID NOs:
- 1, 4, and 7;
- b) SEQ ID NOs:
- 2, 5, and 8;
- and
- c) SEQ ID NOs:
- 3, 6, and 9.
An isolated polypeptide comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to:
- a) SEQ ID NOs:
- 1, 4, and 7;
- b) SEQ ID NOs:
- 2, 4, and 8;
- or
- c) SEQ ID NOs:
- 3, 6, and 9.
An isolated polypeptide comprising an amino acid sequence selected from:
- a) SEQ ID NOs:
- 10, 13, and 16;
- b) SEQ ID NOs:
- 11, 14, and 17;
- or
- c) SEQ ID NOs:
- 12, 15, and 18.
An isolated polypeptide comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to:
- a) SEQ ID NOs:
- 10, 13, and 16;
- b) SEQ ID NOs:
- 11, 14, and 17;
- or
- S c) SEQ ID NOs:
- 12, 15, and 18.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising a heavy chain variable region (VH) comprising an amino acid sequence selected from SEQ ID NOs:
- 28-32.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising a heavy chain variable region (VH) comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs:
- 19-21.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising a light chain variable region (VL) comprising an amino acid sequence selected from SEQ ID NOs:
- 22-24.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising a heavy chain variable region (VL) comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs:
- 22-24.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising a heavy chain variable region (VH) comprising the sequence of SEQ ID NO:
- 19, and a light chain variable region (VL) comprising the sequence of SEQ ID NO:
- 22.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising a heavy chain variable region (VH) comprising the sequence of SEQ ID NO:
- 20, and a light chain variable region (VL) comprising the sequence of SEQ ID NO:
- 23.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising a heavy chain variable region (VH) comprising the sequence of SEQ ID NO:
- 21, and a light chain variable region (VL) comprising the sequence of SEQ ID NO:
- 24.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively, comprise SEQ 1D NOs:
- 1, 4, 7, 10, 13, and 16.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively, comprise SEQ ID NOs:
- 2, 5, 8, 11, 14, and 17.
An antibody or antigen binding fragment thereof that specifically binds human Cluster of Differentiation 19 (CD19), comprising three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain 4% complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively, comprise SEQ ID NOs:
- 3, 6, 9, 12, 15, and 18.
The method of claim 1244, wherein the method is for treating a disease in the subject.
Dependencies are inferred from the claim text.